Capricor Therapeutics, Inc. (CAPR)
NASDAQ: CAPR · Real-Time Price · USD
13.07
+0.17 (1.32%)
At close: Dec 20, 2024, 4:00 PM
13.10
+0.03 (0.23%)
After-hours: Dec 20, 2024, 7:53 PM EST
Capricor Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
Revenue | 23.23 | 25.18 | 2.55 | 0.24 | 0.31 | 1.01 | |
Revenue Growth (YoY) | 65.33% | 886.81% | 941.85% | -21.06% | -69.13% | -39.87% | |
Cost of Revenue | 45.35 | 36.45 | 21.82 | 13.57 | 8.46 | 5.14 | |
Gross Profit | -22.13 | -11.27 | -19.27 | -13.33 | -8.15 | -4.14 | |
Selling, General & Admin | 14.02 | 12.81 | 10.43 | 7.61 | 5.54 | 3.6 | |
Operating Expenses | 14.02 | 12.81 | 10.43 | 7.61 | 5.54 | 3.6 | |
Operating Income | -36.15 | -24.08 | -29.7 | -20.94 | -13.69 | -7.73 | |
Interest & Investment Income | 1.97 | 1.73 | 0.52 | 0.06 | 0.03 | 0.09 | |
Other Non Operating Income (Expenses) | 0.07 | 0.07 | - | - | - | - | |
EBT Excluding Unusual Items | -34.11 | -22.28 | -29.18 | -20.88 | -13.66 | -7.64 | |
Gain (Loss) on Sale of Assets | -0 | -0.01 | -0.03 | -0.01 | - | -0 | |
Other Unusual Items | - | - | 0.19 | 0.87 | - | - | |
Pretax Income | -34.11 | -22.29 | -29.02 | -20.02 | -13.66 | -7.64 | |
Net Income | -34.11 | -22.29 | -29.02 | -20.02 | -13.66 | -7.64 | |
Net Income to Common | -34.11 | -22.29 | -29.02 | -20.02 | -13.66 | -7.64 | |
Shares Outstanding (Basic) | 32 | 27 | 25 | 23 | 16 | 4 | |
Shares Outstanding (Diluted) | 32 | 27 | 25 | 23 | 16 | 4 | |
Shares Change (YoY) | 25.03% | 9.06% | 6.34% | 48.28% | 319.55% | 26.19% | |
EPS (Basic) | -1.07 | -0.83 | -1.18 | -0.87 | -0.88 | -2.06 | |
EPS (Diluted) | -1.07 | -0.83 | -1.18 | -0.87 | -0.88 | -2.06 | |
Free Cash Flow | -38.33 | -27.64 | 1.56 | -18.01 | -10.6 | -6.82 | |
Free Cash Flow Per Share | -1.21 | -1.03 | 0.06 | -0.78 | -0.68 | -1.84 | |
Gross Margin | -95.25% | -44.76% | - | - | - | - | |
Operating Margin | -155.62% | -95.63% | -1163.93% | -8549.86% | -4412.56% | -769.52% | |
Profit Margin | -146.86% | -88.52% | -1137.37% | -8175.86% | -4401.94% | -760.36% | |
Free Cash Flow Margin | -165.00% | -109.79% | 61.02% | -7352.29% | -3417.38% | -678.74% | |
EBITDA | -34.79 | -23.01 | -29.16 | -20.69 | -13.55 | -7.56 | |
EBITDA Margin | -149.78% | -91.39% | - | - | - | - | |
D&A For EBITDA | 1.36 | 1.07 | 0.53 | 0.25 | 0.14 | 0.17 | |
EBIT | -36.15 | -24.08 | -29.7 | -20.94 | -13.69 | -7.73 | |
EBIT Margin | -155.62% | -95.63% | - | - | - | - | |
Revenue as Reported | 23.23 | 25.18 | 2.55 | 0.24 | 0.31 | 1.01 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.